Scenario Planning for Health System Pharmacy
Waiting for clarity is the most expensive strategy in health system pharmacy right now. It just doesn’t show up on a budget line.
Health systems have grown too comfortable with familiar excuses: “We’ll wait for the final rule.” “Let’s see what the payers do.” “We’ll revisit after budget season.”
Each one sounds prudent on its own. Together, they hand the advantage to whoever moves first.
Ask five health system leaders where pharmacy economics will be in three years, and you will get five different answers. What none of them can ignore is how much is already changing. Between 25% and 50% of the infusions your system orders may already be given somewhere else. Starting in 2028, Medicare will negotiate prices on Part B drugs for the first time, and infusion staples like Entyvio and Orencia are on the list. Site-neutral payment is chipping away at outpatient rates. Payers are mandating white bagging. And 340B, a program many pharmacy budgets depend on, remains in flux.
No one can predict which future will arrive. The better move is to stop trying and start planning for several of them.
Why Forecasting Often Falls Short
Most strategic planning starts with a forecast: here is what we expect to happen, so here is what we will do. A forecast is an essential input, but it’s never the solution. Even the most sophisticated models, built to account for change, still land on an expected outcome. When the forces shaping your business are volatile and largely outside your control, a plan built on that single outcome carries real risk.
The solution: scenario planning.
What Is Scenario Planning?
Scenario planning is a structured way to prepare for a range of plausible futures instead of betting on one. It is not forecasting. The goal isn’t guessing right. It’s finding strategies that work no matter which future arrives.
It is especially useful when two conditions are true: uncertainty is high, and your control over the outcome is limited. Health system pharmacy meets both.
The process runs in four steps:
- Define the decision. Name the strategic question and the uncertainty behind it.
- Gather perspectives. Bring in the people who see the problem from different angles: pharmacy, finance, revenue cycle, operations, and clinical leadership.
- Build the futures. Create three or four plausible scenarios.
- Test your options. Run each strategic option through every scenario.
What comes out the other side isn’t a longer plan. It’s a short list of no-regret moves: strategies that win in every future you’ve mapped. Those don’t need to wait for a final rule, a payer decision, or the next budget cycle. They should start now.
That’s the real value of scenario planning. It doesn’t ask you to predict the future. It gives you permission to act before the future is clear.
What Makes a Good Set of Scenarios?
Scenarios are not a best case and a worst case. A useful set has four qualities:
- Plausible. Grounded in what you know today, not speculation.
- Relevant. Tied to a real decision your team is facing.
- Divergent. Different enough from one another to cover a real range of outcomes.
- Challenging. Uncomfortable enough to test assumptions your organization takes for granted.
For health system pharmacy, a starting set might look like this:
| THE FUTURE | WHAT IT LOOKS LIKE | THE QUESTION IT FORCES |
|---|---|---|
| The Long Squeeze | No single shock, just steady erosion. Drug price negotiation reaches more Part B drugs, site-neutral payment expands, rebates thin out, and pharmacy margins shrink a little every year. | If pharmacy margin falls 10–15% over three years, what in our plan still pays for itself? |
| The Reprieve | Proposed policy changes stall, get softened, or are tied up in court. 340B and current payment rules mostly hold for now. The danger is relaxing while competitors use the breathing room to build. | What would we regret not having built if this window closes in 2029? |
| The Great Migration | Payers move decisively to push infusion and specialty care out of hospital outpatient departments and into home, ambulatory, and payer-owned sites. White bagging becomes the norm. Revenue follows patients to the lowest-cost setting, whoever owns it. | When our patients move, will they move to a site we own or one we compete with? |
| The Rebate Reset | The rules for how drug dollars flow are rewritten: PBM reform, rebates paid at the point of sale, and 340B moving from upfront discounts to after-the-fact rebates. The math behind pharmacy cash flow and margin changes. | Which of our programs only work because of how money flows today? |
Stress-Testing Your Pharmacy Strategy
Once the futures are defined, every strategic option on the table gets the same treatment: how does it perform in each scenario? Most options look strong in one future and weak in another. A few hold up in all of them. Those are your no-regret moves.
Take ambulatory infusion. Patients and payers are already moving infusion care toward lower-cost, more convenient settings, regardless of how any single policy plays out. Here is how expanding ambulatory infusion capacity performs in each future:
- The Long Squeeze: As site-neutral payment spreads and margins shrink, a lower-cost, system-owned setting protects volume the hospital outpatient department would otherwise lose.
- The Reprieve: The health system keeps the revenue and the patient relationship, and uses the breathing room to build capacity before competitors do.
- The Great Migration: The system is already positioned in the setting the market now favors.
- The Rebate Reset: The business case rests on where patients receive care, not on how drug dollars flow, so it holds up better than programs built on 340B savings.
Ambulatory infusion is a classic no-regret move. Where you start matters less than you might think. A system with no dedicated sites, one running a pilot, and one with an established program all reach the same conclusion. The only difference is how far and how fast to go.
Not every strategy clears that bar. Expanding specialty pharmacy is a popular move, and in many futures a strong one. Run it through all four, and the picture gets more complicated:
- The Long Squeeze: It still adds margin, but less than projected, because negotiated prices reach specialty drugs and spreads shrink. It remains a positive move, just a thinner one.
- The Reprieve: This is its strongest case. Current economics hold, and the system captures prescriptions it would otherwise lose to outside pharmacies.
- The Great Migration: Results are mixed. Oral specialty drugs aren’t tied to a site of care, so the patient relationship can hold. But if payers steer patients to their own specialty pharmacies, a program without payer network access loses the prescription anyway.
- The Rebate Reset: This is the most exposed case. Programs whose business case depends on 340B savings are hit hardest if those savings arrive later as rebates, or arrive smaller.
That doesn’t make specialty pharmacy a bad bet. It makes it a conditional one. The right move may be to secure payer network access first, model the program without 340B savings, or tie expansion to the market signals below. Scenario planning shows you which strategies to start now and which ones to stage.
Set the Triggers Before the Market Moves
Scenario planning does not end when the planning session does. But the work that follows isn’t watching the headlines and reconvening when something shifts. It’s deciding in advance what will trigger action, and what that action will be.
Think of it like chess. A strong player doesn’t wait for an opponent’s move to start thinking. They’ve already worked out a response to every move worth considering.
For health system pharmacy, that means pairing each signal with a threshold and a decision:
- “If two of our top five payers adopt site of care policies for biologics, we accelerate the second infusion suite.”
- “If 340B shifts to a rebate model for the drugs we dispense most, we rerun the specialty pharmacy business case without upfront discounts.”
- “If the share of our infusion referrals treated outside the system keeps climbing for two straight quarters, we expand capacity closer to where those patients live.”
When a signal crosses its threshold, there’s no committee to reassemble and no new analysis to commission. The decision was made months earlier, when the stakes were lower and the thinking was clearer. All that’s left is to move, and to move with confidence.
Alignment Is the Real Advantage
Alignment is the cure for the paralysis that holds health systems back.
Indecision rarely comes from a lack of information. It comes from different groups defining risk differently. Finance sees margin exposure. Clinical leaders see patient access. Operations sees capacity. Pharmacy sees all three and can’t move without the others.
Scenario planning gives those groups a shared view of risk before a decision is on the table. When finance, clinical, operations, and pharmacy leaders build the futures side by side, they agree on what matters and what they’ll do about it ahead of time. So when the moment arrives, they’re ready to act.
Meanwhile, the competitor down the road is pulling a committee together and spending 12 weeks deciding what to do. By the time they’re ready, you’ve already moved.
Don’t wait for clarity. A Visante pharmacy strategist can help you build the scenarios, find your no-regret moves, and start on them now. Let’s talk.